Immunotherapy Treatment for Triple Negative Breast Cancer
| العنوان: | Immunotherapy Treatment for Triple Negative Breast Cancer |
|---|---|
| المؤلفون: | Mehra Golshan, Elizabeth R Berger, Rachel A. Greenup, Nita Ahuja, Angeleke Saridakis, Tristen S. Park |
| المصدر: | Pharmaceuticals, Vol 14, Iss 763, p 763 (2021) Pharmaceuticals |
| بيانات النشر: | MDPI AG, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | 0301 basic medicine, Oncology, medicine.medical_specialty, medicine.medical_treatment, Receptor expression, Pharmaceutical Science, Review, Targeted therapy, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Pharmacy and materia medica, Internal medicine, Drug Discovery, medicine, Adverse effect, treatment algorithms, Triple-negative breast cancer, Chemotherapy, business.industry, Cancer, Immunotherapy, medicine.disease, RS1-441, 030104 developmental biology, 030220 oncology & carcinogenesis, triple-negative breast cancer, Molecular Medicine, Medicine, immunotherapy, business |
| الوصف: | Triple-negative breast cancer (TNBC) is considered one of the highest-risk subtypes of breast cancer and has dismal prognosis. Local recurrence rate after standard therapy in the early breast cancer setting can be upwards to 72% in 5 years, and in the metastatic setting, the 5-year overall survival is 12%. Due to the lack of receptor expression, there has been a paucity of targeted therapeutics available, with chemotherapy being the primary option for systemic treatment in both the neoadjuvant and metastatic setting. More recently, immunotherapy has revolutionized the landscape of cancer treatment, particularly immune checkpoint inhibitor (ICI) therapy, with FDA approval in over 20 types of cancer since 2011. Compared to other cancer types, breast cancer has been traditionally thought of as being immunologically cold; however, TNBC has demonstrated the most promise with immunotherapy use, a timely discovery due to its lack of targeted therapy options. In this review, we summarize the trials using checkpoint therapy in early and metastatic TNBC, as well as the development of biomarkers and the importance of immune related adverse events (IRAEs), in this disease process. |
| اللغة: | English |
| تدمد: | 1424-8247 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93551050d0e133b4c088e9f218b2c8dc https://www.mdpi.com/1424-8247/14/8/763 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....93551050d0e133b4c088e9f218b2c8dc |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14248247 |
|---|